These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1879 related articles for article (PubMed ID: 31623593)

  • 1. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation.
    Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M
    BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical implications of TERT promoter mutation on IDH mutation and MGMT promoter methylation in diffuse gliomas.
    Kim HS; Kwon MJ; Song JH; Kim ES; Kim HY; Min KW
    Pathol Res Pract; 2018 Jun; 214(6):881-888. PubMed ID: 29650441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients.
    Takahashi Y; Nakamura H; Makino K; Hide T; Muta D; Kamada H; Kuratsu J
    World J Surg Oncol; 2013 Oct; 11():284. PubMed ID: 24160898
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The frequency and prognostic effect of TERT promoter mutation in diffuse gliomas.
    Lee Y; Koh J; Kim SI; Won JK; Park CK; Choi SH; Park SH
    Acta Neuropathol Commun; 2017 Aug; 5(1):62. PubMed ID: 28851427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A combination of TERT promoter mutation and MGMT methylation status predicts clinically relevant subgroups of newly diagnosed glioblastomas.
    Arita H; Yamasaki K; Matsushita Y; Nakamura T; Shimokawa A; Takami H; Tanaka S; Mukasa A; Shirahata M; Shimizu S; Suzuki K; Saito K; Kobayashi K; Higuchi F; Uzuka T; Otani R; Tamura K; Sumita K; Ohno M; Miyakita Y; Kagawa N; Hashimoto N; Hatae R; Yoshimoto K; Shinojima N; Nakamura H; Kanemura Y; Okita Y; Kinoshita M; Ishibashi K; Shofuda T; Kodama Y; Mori K; Tomogane Y; Fukai J; Fujita K; Terakawa Y; Tsuyuguchi N; Moriuchi S; Nonaka M; Suzuki H; Shibuya M; Maehara T; Saito N; Nagane M; Kawahara N; Ueki K; Yoshimine T; Miyaoka E; Nishikawa R; Komori T; Narita Y; Ichimura K
    Acta Neuropathol Commun; 2016 Aug; 4(1):79. PubMed ID: 27503138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TERT promoter mutation confers favorable prognosis regardless of 1p/19q status in adult diffuse gliomas with IDH1/2 mutations.
    Arita H; Matsushita Y; Machida R; Yamasaki K; Hata N; Ohno M; Yamaguchi S; Sasayama T; Tanaka S; Higuchi F; Iuchi T; Saito K; Kanamori M; Matsuda KI; Miyake Y; Tamura K; Tamai S; Nakamura T; Uda T; Okita Y; Fukai J; Sakamoto D; Hattori Y; Pareira ES; Hatae R; Ishi Y; Miyakita Y; Tanaka K; Takayanagi S; Otani R; Sakaida T; Kobayashi K; Saito R; Kurozumi K; Shofuda T; Nonaka M; Suzuki H; Shibuya M; Komori T; Sasaki H; Mizoguchi M; Kishima H; Nakada M; Sonoda Y; Tominaga T; Nagane M; Nishikawa R; Kanemura Y; Kuchiba A; Narita Y; Ichimura K
    Acta Neuropathol Commun; 2020 Nov; 8(1):201. PubMed ID: 33228806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution.
    Boots-Sprenger SH; Sijben A; Rijntjes J; Tops BB; Idema AJ; Rivera AL; Bleeker FE; Gijtenbeek AM; Diefes K; Heathcock L; Aldape KD; Jeuken JW; Wesseling P
    Mod Pathol; 2013 Jul; 26(7):922-9. PubMed ID: 23429602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma.
    Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K
    Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma.
    Wiestler B; Capper D; Sill M; Jones DT; Hovestadt V; Sturm D; Koelsche C; Bertoni A; Schweizer L; Korshunov A; Weiß EK; Schliesser MG; Radbruch A; Herold-Mende C; Roth P; Unterberg A; Hartmann C; Pietsch T; Reifenberger G; Lichter P; Radlwimmer B; Platten M; Pfister SM; von Deimling A; Weller M; Wick W
    Acta Neuropathol; 2014 Oct; 128(4):561-71. PubMed ID: 25008768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors.
    Mellai M; Monzeglio O; Piazzi A; Caldera V; Annovazzi L; Cassoni P; Valente G; Cordera S; Mocellini C; Schiffer D
    J Neurooncol; 2012 May; 107(3):617-31. PubMed ID: 22287028
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT.
    Pekmezci M; Rice T; Molinaro AM; Walsh KM; Decker PA; Hansen H; Sicotte H; Kollmeyer TM; McCoy LS; Sarkar G; Perry A; Giannini C; Tihan T; Berger MS; Wiemels JL; Bracci PM; Eckel-Passow JE; Lachance DH; Clarke J; Taylor JW; Luks T; Wiencke JK; Jenkins RB; Wrensch MR
    Acta Neuropathol; 2017 Jun; 133(6):1001-1016. PubMed ID: 28255664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
    Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
    Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessing CpG island methylator phenotype, 1p/19q codeletion, and MGMT promoter methylation from epigenome-wide data in the biomarker cohort of the NOA-04 trial.
    Wiestler B; Capper D; Hovestadt V; Sill M; Jones DT; Hartmann C; Felsberg J; Platten M; Feiden W; Keyvani K; Pfister SM; Wiestler OD; Meyermann R; Reifenberger G; Pietsch T; von Deimling A; Weller M; Wick W
    Neuro Oncol; 2014 Dec; 16(12):1630-8. PubMed ID: 25028501
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative Analysis of the Prognostic Significance of IDH,TERT, EGFR and MGMT Status in Patients with Adult Non-H3-Altered Grade 4 Gliomas: A Prospective Cohort Study.
    Alimohamadi M; Larijani A; Pour-Rashidi A; Farzin M; Ebrahimi H; Rahmani M; Hendi K; Yarandi KK; Aghajanian S; Shirani M
    World Neurosurg; 2024 Jan; 181():e628-e639. PubMed ID: 37914076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting.
    Hewer E; Prebil N; Berezowska S; Gutt-Will M; Schucht P; Dettmer MS; Vassella E
    Virchows Arch; 2017 Nov; 471(5):641-649. PubMed ID: 28823044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term survival in primary glioblastoma with versus without isocitrate dehydrogenase mutations.
    Hartmann C; Hentschel B; Simon M; Westphal M; Schackert G; Tonn JC; Loeffler M; Reifenberger G; Pietsch T; von Deimling A; Weller M;
    Clin Cancer Res; 2013 Sep; 19(18):5146-57. PubMed ID: 23918605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. TERT promoter mutations contribute to subset prognostication of lower-grade gliomas.
    Chan AK; Yao Y; Zhang Z; Chung NY; Liu JS; Li KK; Shi Z; Chan DT; Poon WS; Zhou L; Ng HK
    Mod Pathol; 2015 Feb; 28(2):177-86. PubMed ID: 25081751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of MGMT Promoter Methylation With Survival in Low-grade and Anaplastic Gliomas After Alkylating Chemotherapy.
    Kinslow CJ; Mercurio A; Kumar P; Rae AI; Siegelin MD; Grinband J; Taparra K; Upadhyayula PS; McKhann GM; Sisti MB; Bruce JN; Canoll PD; Iwamoto FM; Kachnic LA; Yu JB; Cheng SK; Wang TJC
    JAMA Oncol; 2023 Jul; 9(7):919-927. PubMed ID: 37200021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients.
    Mur P; Rodríguez de Lope Á; Díaz-Crespo FJ; Hernández-Iglesias T; Ribalta T; Fiaño C; García JF; Rey JA; Mollejo M; Meléndez B
    J Neurooncol; 2015 May; 122(3):441-50. PubMed ID: 25682093
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 94.